Alkem Laboratories Ltd

- The U.S. CDMO plant recently became operational, with ongoing ramp-up expected to reach full capacity and INR 300 crores revenue run-rate in 12 to 18 months. Future expansion investments will be considered based on opportunity and demand. - Medtech business is in investment phase, with planned expenses on product filings and approvals for new markets; breakeven expected by FY '28. - No immediate large-scale capex indicated beyond current operations, though management remains open to additional investments if strategic opportunities arise. - India remains the core market with continuous brand/market investments; strategic acquisitions considered when right opportunities emerge. - R&D investments continue, expected to be around 4%-5% of revenues, with filings mostly concentrated in Q4. - Overall, planned investments and opex for new businesses (CDMO, Medtech) are factored into margin and growth guidance.

- India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27. - Domestic market remains core; strategic initiatives support sustained momentum. - Non-U.S. export markets projected to grow at high teens to around 20% annually. - U.S. CDMO plant: Operationally just started; expected revenue ramp-up to INR300 crores annual run rate in 12-18 months. - MedTech business: Break-even anticipated in FY28, with moderate operational expenses during ramp-up. - Enzene business (U.S.): Revenues around INR70-80 crores expected in FY26, with INR50 crores quarterly opex; breakeven targeted in 12-18 months. - Overall, double-digit growth is maintained across geographies with new launches contributing to expansion.

- Alkem expects continued strong growth across India, U.S., and key international markets supported by new product launches. - India business is forecasted to outperform the market by 100 to 150 basis points with a double-digit growth outlook for FY27. - U.S. business growth is expected to improve to double digits this year, up from earlier mid-single-digit guidance. - Non-U.S. international markets are projected to deliver high teens to around 20% growth annually. - EBITDA margin is anticipated to expand by approximately 100 basis points from FY27 onwards, inclusive of planned investments in MedTech and CDMO businesses. - The company targets at least 1% year-on-year improvement in overall margins starting FY27. - Enzene U.S. CDMO plant is expected to break even in 12-18 months, contributing positively thereafter. - Medtech business is expected to break even by FY28 with moderate opex losses beforehand. - Overall, Alkem aims for sustained margin expansion alongside revenue growth driving future earnings and EPS growth.

- The newly operational U.S. CDMO plant has just started and has an estimated order book expected to generate around INR 300 crores in revenue over the next 12 to 18 months. - Current quarterly revenues from the U.S. CDMO business are around INR 15-20 crores, with operating expenses at approximately INR 50 crores per quarter as ramp-up continues. - Management is closely monitoring the order book and plant output, with potential for further investment if demand warrants it. - No specific number of projects or detailed order backlog figures were disclosed, as Alkem does not provide project-level details publicly. - Enzene U.S. plant expects to reach an annualized revenue run-rate of INR 300 crores in 12-18 months from the current operations. - Management is optimistic about ramp-up and scaling opportunities but cautious, awaiting better visibility from current bookings and order flow.

- There is no specific mention of any current or planned new fundraising through debt or equity in the provided transcript. - The management stated having good cash on the balance sheet, indicating no immediate need for external funding. - They are focused on strategic growth and acquiring businesses at the right value but did not mention raising funds to support this. - Investments are mainly through internal accruals, especially for the CDMO plant and Medtech ventures. - No explicit commentary on upcoming debt or equity issuance was provided during the Q&A.